Add to ORKGThe pharmaceutical sector has unusual prominence in debates about IP policy, and has served as the front line for national and international controversies about the relationship between IPRs, R&D incentives, pricing and access to medicines. Notwithstanding the intensity of debate, on some crucial questions there is relatively little empirical evidence to support policy-making
In today’s world, we live with the notion that economic health and firm competitiveness are cl...
Over the past fifteen years, the United States and other developed countries have employed trade agr...
Intellectual property rights (IPR) have been defined as ideas, inventions, and creative expressions ...
This report focuses on the relationship between intellectual property right (IPR) provisions in inte...
Economists view intellectual property rights (IPRs) as policy tools for encouraging innovation, but ...
This paper analyses the inadequacy of IPRs to foster R&D for vaccines and drugs for neglected di...
Economists view intellectual property rights (IPRs) as policy tools for encouraging innovation. Ther...
Are intellectual property rights institutions meant to foster innovative activity or conversely to s...
Over the past fifteen years, the United States and other developed countries have employed trade agr...
Intellectual Property (IP) is a pharmaceutical or Biotech Company’s most valuable resource, and its ...
Economists view intellectual property rights (IPRs) as policy tools for encouraging innovation, but ...
Economists view intellectual property rights (IPRs) as policy tools for encouraging innovation. Ther...
Economists view intellectual property rights (IPRs) as policy tools for encouraging innovation. Ther...
This title contains discussions that explore the role of competition policy and intellectual propert...
This study explores how an 'Intellectual Property Rights (IPR)/trade regime' has generated a particu...
In today’s world, we live with the notion that economic health and firm competitiveness are cl...
Over the past fifteen years, the United States and other developed countries have employed trade agr...
Intellectual property rights (IPR) have been defined as ideas, inventions, and creative expressions ...
This report focuses on the relationship between intellectual property right (IPR) provisions in inte...
Economists view intellectual property rights (IPRs) as policy tools for encouraging innovation, but ...
This paper analyses the inadequacy of IPRs to foster R&D for vaccines and drugs for neglected di...
Economists view intellectual property rights (IPRs) as policy tools for encouraging innovation. Ther...
Are intellectual property rights institutions meant to foster innovative activity or conversely to s...
Over the past fifteen years, the United States and other developed countries have employed trade agr...
Intellectual Property (IP) is a pharmaceutical or Biotech Company’s most valuable resource, and its ...
Economists view intellectual property rights (IPRs) as policy tools for encouraging innovation, but ...
Economists view intellectual property rights (IPRs) as policy tools for encouraging innovation. Ther...
Economists view intellectual property rights (IPRs) as policy tools for encouraging innovation. Ther...
This title contains discussions that explore the role of competition policy and intellectual propert...
This study explores how an 'Intellectual Property Rights (IPR)/trade regime' has generated a particu...
In today’s world, we live with the notion that economic health and firm competitiveness are cl...
Over the past fifteen years, the United States and other developed countries have employed trade agr...
Intellectual property rights (IPR) have been defined as ideas, inventions, and creative expressions ...